USFDA declines to approve this Lung Cancer drug

The health regulator's (US Food and Drugs Administration) decision is in line with an advisory panel's recommendation to not approve the drug.

115
Medicine
Picture: Pixabay

Last Updated on November 27, 2022 by The Health Master

New Delhi: Spectrum Pharmaceuticals Inc said that the U.S. Food and Drug Administration (USFDA) declined to approve its experimental lung cancer drug, citing the need for an additional study.

The company now plans to de-prioritize the development of the drug, called poziotinib, and said it was in the process of cutting 75 percent of its research and development workforce.

Spectrum had 164 employees as of Dec 31, 2021.

The health regulator’s decision is in line with an advisory panel’s recommendation to not approve the drug.

USFDA declines to approve expanded use of this Antipsychotic drug

USFDA declines to approve this Urinary Tract Infection Drug

USFDA declines to approve this Anti-seizure drug

USFDA declines to authorise this viral skin disease treatment

USFDA declines pediatric EUA for vaccine Covaxin

USFDA declines to approve Gilead’s HIV drug on this concern

NPPA fixes Retail Price of 40 formulations: November 2022

IPC adds one IP Reference Standard & 20 new impurities to IP 2022

USFDA issues warning letter to Glenmark’s Goa facility

DCGI gives nod to Intranasal C-19 booster dose

USFDA issues Form 483 with 8 observations to Lupin

Drug recall: FDA issues nationwide recall for Ferric Carboxymaltose

Govt issues draft notification to amend NDCTR, 2019

Haryana: Sathi app launched to check Drugs abuse

CDSCO approves 4 more Medical Device Testing Labs (MDTL)

Latest Notifications regarding Pharmaceuticals

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news